Modulation of junctional signaling by BVES in colorectal carcinoma

BVES 对结直肠癌中连接信号的调节

• 批准号: 8332389
• 负责人: Christopher S. Williams
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8332389
• 关键词: Address; Adenomatous Polyps; Adherens Junction; Adhesions; Adhesives; Affect; Anchorage-Independent Growth; Attenuated; BCAR3 gene; Binding; Biological Assay; Biological Markers; Biology; Blood Vessels; Breast; CDK4 gene; Cancer Control; Cancer Etiology; Cancer cell line; Cell Adhesion Molecules; Cell Culture Techniques; Cell Cycle; Cell Line; Cell Proliferation; Cell membrane; Cell-Cell Adhesion; Cells; Clinical; Colon; Colon Carcinoma; Colorectal Cancer; Complex; CpG Islands; Cyclin D1; Cytokeratin; Data; Decitabine; Development; Diagnosis; Diagnostic; Disease; Dominant-Negative Mutation; Dysmyelopoietic Syndromes; E-Cadherin; E-Cadherin Staining Method; Epigenetic Process; Epithelial; Epithelial Cells; Event; FDA approved; Functional disorder; Gene Activation; Genetic; Growth; Health Personnel; Healthcare Systems; Human; Hybrids; Hypermethylation; Incidence; Inflammatory; Large Intestine Carcinoma; Link; Malignant - descriptor; Malignant Epithelial Cell; Malignant Neoplasms; Malignant neoplasm of ovary; Maps; Mechanics; Mediating; Membrane; Mesenchymal; Methylation; Modeling; Molecular; Morphology; Mus; Myosin ATPase; Neoplasm Metastasis; Nuclear; Nude Mice; Ovarian; Pathology; Pathway interactions; Phenotype; Play; Process; Proteins; Proto-Oncogenes; RHOA gene; Regulator Genes; Regulatory Pathway; Reporter; Repression; Resistance; Role; Sampling; Screening procedure; Signal Pathway; Signal Transduction; Small Interfering RNA; Staging; Structure; Surveys; Testing; Tight Junctions; Transcriptional Activation; Treatment Efficacy; Tumor Biology; Tumor Suppressor Proteins; United States; United States Department of Veterans Affairs; Veterans; Vimentin; WNT Signaling Pathway; Wound Healing; Xenograft procedure; Yeasts; attenuation; base; blood vessel restoration; burden of illness; cancer cell; cancer diagnosis; carcinogenesis; cell motility; claudin 3; colorectal cancer prevention; corneal epithelium; design; in vivo; insight; knock-down; malignant phenotype; malignant stomach neoplasm; migration; monolayer; mortality; new therapeutic target; novel; novel diagnostics; overexpression; programs; promoter; rho; splenic capsule; therapeutic target; tumor; tumor growth; tumorigenesis; tumorigenic

DESCRIPTION (provided by applicant): Colorectal cancer (CRC) has a US incidence rate of almost 150,000 cases encompassing over 10% of new cancer diagnoses. In 2006 Within the Veterans Administration Healthcare System there were 4500 new cases and of those 650 were at advanced stage with very limited treatment options. Understanding the basic biology of underlying malignant transformation is critical in identifying new therapeutic targets and implementable strategies. Epithelial junctional pathology is common in malignancy. Decreased expression or mislocalization of E-cadherin, an adherens junction protein, has long been implicated in CRC. Claudin -3, -4, and -7, all transmembrane tight junction proteins, are overexpressed in ovarian, CRC, and gastric cancers and knock-down of claudin-3 and -4 in ovarian cancer cell lines leads to reduced invasiveness. Thus, both tight and adherens junctional dysfunction is implicated in CRC. BVES is a tight junction associated protein which when suppressed induces mesenchymal transformation in human corneal epithelial cells. Because mesenchymal transformation occurs in late stage CRC, facilitating metastasis, we postulated that BVES may be altered in CRC. We found decreased expression of BVES in CRC. BVES was underexpressed in adenomatous polyps indicating that loss of expression is an early event, likely implicating BVES in regulating additional pro- tumorigenic programs in addition to potentially contributing to metastasis. We determined the mechanism of underexpression was via transcriptional silencing via promoter hypermethylation, occurring in a large fraction of clinical samples, and virtually all CRC cell lines surveyed. We tested the functional relevance of BVES loss by restoring its expression in LIM2405 cells. These cells are weakly adherent, highly proliferative, migratory, and invasive. BVES strikingly reversed all of these phenotypes causing "epithealization" of the line with conversion to epithelial morphology and increased expression of cytokeratin and reciprocal loss of vimentin. These phenotypic changes were associated with increased E-cadherin expression with a shift in ¿-catenin distribution to the cell membrane with associated decreased WNT reporter activity, implicating BVES in regulating a known cancer-signaling pathway. Additionally, in investigating the mesenchymal phenotype, we observed increased GEF-H1, BVES, Zo-1 membrane accumulation with decreased RHOA activity; indicating BVES could regulate Rho signaling. Furthermore, BVES expression in LIM2405 cells attenuated tumor growth as nude mouse xenografts and blocked SW620 metastasis. Collectively, this data suggests that BVES functions as a tumor suppressor in epithelial malignancy, thus BVES may represent a new diagnostic marker and/or therapeutic target in cancer. Much remains to be known about BVES function in epithelial malignancy. In this proposal we structure three specific aims designed to understand the role of BVES in tumor biology. First we will use murine genetic approaches to test for BVES cooperation with APC in promoting tumorigenesis and to test for a role for BVES in inflammatory carcinogenesis. We also propose mechanistic structure function studies to map BVES functional domains contributing to BVES dependent phenotypes. We have performed a yeast 2-hybrid screen and identified a panel of BVES interacting proteins. We propose characterizing the interaction between BVES and BCAR3 a breast protooncogene with GEF activity known to regulate RHO dependent processes. Lastly, we will determine if restoration of BVES expression using epigenetic modifying agents reverses the malignant phenotype of CRC cells. This could provide support for using BVES methylation as a diagnostic marker to guide therapy. Through these studies we will gain fundamental insight into how loss of BVES contributes to malignant progression, potentially providing evidence that supports developing BVES as a therapeutic target or diagnostic marker in colorectal carcinoma and addressing Provocative Question #20 from the NCI "...can biomarkers or signatures be identified that can serve as predictors or surrogates of therapeutic efficacy?".

描述（由申请人提供）： 结直肠癌 (CRC) 在美国的发病率接近 150,000 例，占新诊断癌症的 10% 以上。 2006 年，退伍军人管理局医疗保健系统内有 4500 例新病例，其中 650 例处于晚期，治疗选择非常有限。了解潜在恶性转化的基本生物学对于确定新的治疗靶点和可实施的策略至关重要。上皮连接病理学在恶性肿瘤中很常见。 E-钙粘蛋白（一种粘附连接蛋白）的错误定位长期以来一直与 CRC 相关，Claudin -3、-4 和 -7（所有跨膜紧密连接蛋白）在卵巢癌、CRC 和胃癌中过度表达，并且与 CRC 相关。卵巢癌细胞系中的claudin-3和-4导致侵袭性降低，因此，紧密连接和粘附连接功能障碍与BVES相关。由于间质转化发生在晚期 CRC 中，从而促进了转移，因此我们推测 BVES 在 CRC 中可能发生改变，我们发现 BVES 在 CRC 中表达不足。表明表达缺失是一个早期事件，可能意味着 BVES 除了可能导致转移之外，还调节其他促肿瘤发生程序。确定低表达的机制是通过启动子高甲基化导致的转录沉默，这种情况发生在大部分临床样本中，并且几乎所有调查的 CRC 细胞系中我们都通过恢复 BVES 在 LIM2405 细胞中的表达来测试其功能相关性。粘附性、高度增殖性、迁移性和侵袭性BVES显着逆转了所有这些表型，导致细胞系“上皮化”，转化为上皮形态并增加了表达。这些表型变化与 E-钙粘蛋白表达增加和 ¿ 的变化相关。 -连环蛋白分布到细胞膜上与 WNT 报告基因活性降低相关，这表明 BVES 调节已知的癌症信号传导途径。此外，在研究间充质表型时，我们观察到 GEF-H1、BVES、Zo-1 膜积累增加，而 RHOA 减少。活性；表明 BVES 可以调节 Rho 信号传导，此外，LIM2405 细胞中的 BVES 表达可减弱裸鼠异种移植物的肿瘤生长并阻断 SW620 转移。总的来说，这些数据表明 BVES 在上皮恶性肿瘤中发挥肿瘤抑制作用，因此 BVES 可能代表癌症的新诊断标记和/或治疗靶标。在本提案中，我们构建了三个关于 BVES 功能的知识。旨在了解 BVES 在肿瘤生物学中的作用的具体目标首先，我们将使用小鼠遗传学方法来测试 BVES 与 APC 在促进肿瘤发生方面的合作，并测试 BVES 在肿瘤发生中的作用。我们还提出了机制结构功能研究，以绘制有助于 BVES 表型的 BVES 功能域。我们进行了酵母 2 杂交筛选，并鉴定了一组 BVES 依赖性相互作用蛋白。最后，我们将确定使用表观遗传修饰剂恢复 BVES 表达是否可以逆转 CRC 细胞的恶性表型。可以为使用 BVES 甲基化作为诊断标记物来指导治疗提供支持，通过这些研究，我们将深入了解 BVES 的缺失如何导致恶性进展，并可能提供支持将 BVES 作为结直肠癌的治疗靶点或诊断标记物的证据。并解决了 NCI 的挑衅性问题 #20“……能否识别出可以作为治疗效果的预测因子或替代指标的生物标志物或特征？”。